For CLL patients without TP53 aberration and those with TP53 aberration, initiating treatment with VO as 1L was estimated to reduce drug costs by CAD 169,341 and CAD 293,731 per patient, respectively, compared to treatment sequences without VO over 10 years. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.